SCHEMBL5669102

SCHEMBL5669102

CCOC(=O)c1cccc2ncccc12

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.54
CDC25B P30305 2/20 0.51
NSD2 O96028 1/20 0.51
HTT P42858 1/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
PKM P14618 1/20 0.51
ELANE P08246 3/20 0.49
NUDT1 P36639 1/20 0.49
CLEC4M Q9H2X3 1/20 0.48
CDC25A P30304 1/20 0.48
CDC25C P30307 1/20 0.48
ALDH1A1 P00352 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MAPT P10636 2/20 0.47
TP53 P04637 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1768671 0.89 NUDT1 (0.57) TSHRCDC25BMEN1KMT2APKM
SCHEMBL29523397 0.89 NUDT1 (0.57) TSHRCDC25BMEN1KMT2APKM
SCHEMBL4837150 0.85 NSD2 (0.49) NSD2HTTMEN1KMT2APKM
SCHEMBL827213 0.83 KDM4E (0.59) NSD2HTTMEN1KMT2AHSD17B10
SCHEMBL28207288 0.82 MEN1 (0.58) TSHRCDC25BMEN1KMT2APKM
SCHEMBL7000087 0.82 NSD2 (0.45) CDC25BNSD2HTTMEN1KMT2A
SCHEMBL9150759 0.82 TSHR (0.73) TSHRCDC25BMEN1KMT2ACLEC4M
SCHEMBL3412270 0.81 MEN1 (0.52) TSHRHTTMEN1KMT2APKM
SCHEMBL1161019 0.81 ELANE (0.46) TSHRHTTMEN1KMT2APKM
SCHEMBL4840021 0.81 NSD2 (0.45) NSD2HTTMEN1KMT2APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1670446-A2 METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION JAPAN TOBACCO INC. (JP) 2006-06-21 EP claimed
CN-1784401-A Novel fused triazolones and uses thereof ASTRAZENECA AB (SE) 2006-06-07 CN claimed
WO-2005030185-A2 METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION JAPAN TOBACCO INC. (JP) 2005-04-07 WO claimed
CN-1458840-A Pharmaceutical composition of cholesteryl ester transfer protein inhibitor PFIZER PROD INC (US) 2003-11-26 CN claimed
EP-1305007-A2 PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS Pfizer Products Inc. (US) 2003-05-02 EP claimed
WO-2002011710-A2 PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS PFIZER PRODUCTS INC. (US) 2002-02-14 WO claimed
US-20250287942-A1 FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-09-18 US disclosed
WO-2023205458-A2 FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-10-26 WO disclosed
EP-3183250-B1 PROCESS FOR PREPARING CRYSTALLINE ORGANIC SEMICONDUCTOR MATERIAL CLAP CO LTD (KR) 2023-10-04 EP disclosed
EP-3183757-B1 ORGANIC SEMICONDUCTOR COMPOSITION COMPRISING LIQUID MEDIUM CLAP CO LTD (KR) 2022-05-04 EP disclosed
CN-107004768-B Organic semiconductor composition containing a liquid medium 巴斯夫欧洲公司 2020-08-21 CN disclosed
CN-107074857-A Method for preparing crystallization organic semiconducting materials 巴斯夫欧洲公司 2017-08-18 CN disclosed
CN-107004768-A Organic semiconductor composition containing a liquid medium 巴斯夫欧洲公司 2017-08-01 CN disclosed
CN-1458840-A Pharmaceutical composition of cholesteryl ester transfer protein inhibitor PFIZER PROD INC (US) 2003-11-26 CN disclosed
EP-1305007-A2 PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS Pfizer Products Inc. (US) 2003-05-02 EP disclosed
EP-1228043-A1 ISOQUINOLINE AND QUINAZOLINE DEIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY SMITHKLINE BEECHAM PLC (GB) 2002-08-07 EP disclosed
WO-2002011710-A2 PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS PFIZER PRODUCTS INC. (US) 2002-02-14 WO disclosed
WO-2001032626-A1 ISOQUINOLINE AND QUINAZOLINE DERIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY SMITHKLINE BEECHAM P.L.C. (GB) 2001-05-10 WO disclosed
JP-2000044561-A PYRROLOQUINOLINE DERIVATIVE AND ITS PRODUCTION KYORIN PHARMACEUT CO LTD 2000-02-15 JP disclosed
US-4968803-A FLUORINE AS OXIDANT ALLIED-SIGNAL INC. (US) 1990-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250287942-A1 FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS ACHE, BCHE, DDT TSHR 4454/4885CDC25B 1205/4885NSD2 563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.